Stocks › NVO
Novo Nordisk A/S (NVO) stock analysis
SKIP 1% confidence · analysed Oct 1, 2026
On Oct 1, 2026, our model rated Novo Nordisk A/S (NVO) SKIP with 1% confidence at a price of $37.61. That means the signals cancel out; the model sees no clear edge either way.
Technical picture
The 14-day RSI is 24, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.
MACD is below its signal line, so short-term momentum is pointing down.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is only 0.5x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $61.11 and the swing low is $34.15; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 4.37, which looks expensive relative to its growth.
The company reports a profit margin of 35.3% and revenue growth of +2.1%.
In its latest quarter it earned $6.18 per share, which beat the $4.98 analysts expected, with revenue +2.1% year over year.
Wall Street's average rating is 2.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "hold", with an average price target of $45.76.
The next earnings report is expected around Nov 4, 2026; prices often move sharply around earnings.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.01 (SKIP). Technicals: RSI 24.03, MACD bearish, price below SMA50. Fundamentals: PEG 4.37, margin 35.3%, revenue growth 2.1%. Financial results: YoY revenue +2.1%, last EPS surprise +24.1%, next earnings 2026-11-04. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Memory: 4 prior look(s); 0% of directional calls matched later price. Reference price $37.62; no trade levels (SKIP).
Past ratings for NVO
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 1, 2026 | SKIP | 1% | $37.61 | — | |
| Sep 28, 2026 | SKIP | 1% | $38.34 | -1.9% | |
| Sep 24, 2026 | WEAK SELL | 21% | $38.17 | -1.5% | ✔ right direction |
| Sep 23, 2026 | SKIP | 3% | $38.75 | -2.9% |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
OSCR · PCRX · PGNY · PHR · PRGO · SDZNY · SNN · STE · TCMD · TKNO · UNH · ZBH
Frequently asked questions
Is NVO a buy right now?
As of Oct 1, 2026, our automated model rates Novo Nordisk A/S (NVO) SKIP with 1% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
When does Novo Nordisk A/S report earnings next?
The next earnings report is expected around Nov 4, 2026.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.